Introduction Bevacizumab is a humanized monoclonal antibody targeting all circulating vascular endothelial growth factor A (VEGF-A) isoforms, preventing VEGF-A from binding to vascular endothelial growth factor receptors (VEGFR) and thereby inhibiting angiogenesis (1). By normalizing tumor vasculature, bevacizumab enhances the delivery of cytotoxic
Woman presented with Fever of Unknown Origin
7726 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Black Lesion in Old Female
1972 Reached5 Comments11 Likes
Male with Jaw Pain and Abdominal Bloating
790 Reached24 Comments26 Likes
Case of Adolescent with Severe Macrocytic Anaemia
52859 Reached502 Comments51 Likes